| NCT07064759 | Single Intravitreal Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | RECRUITING | PHASE3 | 2025-07 | 2029-02 | 2028-11 |
| NCT06864988 | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | RECRUITING | PHASE3 | 2025-03-03 | 2028-06 | 2027-06 |
| NCT05930561 | 4D-150 in Patients With Diabetic Macular Edema | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-08-09 | 2029-02-28 | 2029-02-28 |
| NCT05629559 | 4D-310 in Adults With Fabry Disease and Cardiac Involvement | RECRUITING | PHASE1, PHASE2 | 2022-10-16 | 2030-06 | 2026-06 |
| NCT05248230 | 4D-710 in Adult Patients With Cystic Fibrosis | RECRUITING | PHASE1, PHASE2 | 2022-03-29 | 2030-01 | 2026-12 |
| NCT05197270 | 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | RECRUITING | PHASE1, PHASE2 | 2021-12-09 | 2031-01 | 2027-03 |
| NCT04519749 | An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-09-01 | 2030-06 | 2026-01 |
| NCT04517149 | 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-06-09 | 2029-05 | 2026-06 |
| NCT04483440 | Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-06-02 | 2027-08-31 | 2027-05-26 |